Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Merck
AstraZeneca
Julphar
Novartis
Express Scripts
Colorcon
Harvard Business School
Teva
Accenture

Generated: October 21, 2017

DrugPatentWatch Database Preview

VIIBRYD Drug Profile

« Back to Dashboard

Which patents cover Viibryd, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Forest Labs Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-two patent family members in thirty-two countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

Summary for Tradename: VIIBRYD

US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list54
Clinical Trials: see list16
Patent Applications: see list27
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIIBRYD at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXYesNo► Subscribe► Subscribe ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VIIBRYD

Drugname Dosage Strength RLD Submissiondate
vilazodone hydrochlorideTablets10 mg, 20 mg, and 40 mgVIIBRYD1/21/2015

Non-Orange Book Patents for Tradename: VIIBRYD

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,927,552Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
7,381,726Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
8,318,744Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
8,921,375Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
9,624,204Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
7,981,894Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIIBRYD

Country Document Number Estimated Expiration
Japan2004534803► Subscribe
Japan2010132688► Subscribe
Poland208708► Subscribe
MexicoPA03011723► Subscribe
Australia7424494► Subscribe
Canada2782515► Subscribe
Hungary229601► Subscribe
Australia679774► Subscribe
Norway306948► Subscribe
South Africa200400329► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Novartis
Farmers Insurance
Merck
Dow
Federal Trade Commission
US Army
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot